XRP price wobbles after U.S. Senate delays CLARITY Act markup — what traders watch next
16 January 2026
1 min read

XRP price wobbles after U.S. Senate delays CLARITY Act markup — what traders watch next

New York, Jan 16, 2026, 17:21 EST — After-hours.

  • XRP hovered around $2.07 in late New York trading, edging down slightly for the day
  • The Senate Banking Committee has delayed the scheduled markup on the CLARITY Act following objections from Coinbase’s CEO.
  • Ripple highlights new strides in European licensing while investors focus on upcoming U.S. legislative deadlines

XRP slipped Friday as U.S. senators delayed a crucial move on a long-awaited crypto market-structure bill, cooling expectations for quicker regulatory clarity.

This battle goes beyond procedure. The bill aims to clarify the boundaries between U.S. regulators, defining when a token qualifies as a security or a commodity — a key issue that still shapes how major exchanges list and trade coins.

When it comes to XRP, the token linked to payments company Ripple, policy headlines often drive trading just as much as shifts in bond yields.

XRP hovered near $2.07 late in New York trading, slipping about 0.1% after dropping 2.8% on Thursday. Throughout the session, it fluctuated between roughly $2.03 and $2.09. (Investing)

The Senate Banking Committee delayed its scheduled debate after Coinbase CEO Brian Armstrong said the exchange couldn’t back the bill as it stands. Armstrong called the proposal riddled with “too many issues” and added, “We’d rather have no bill than a bad bill.” According to Reuters, the legislation would ban crypto firms from paying interest just for holding stablecoins but would still allow rewards linked to actions like sending payments or joining loyalty programs. (Reuters)

The committee had originally scheduled an executive session for Thursday to review H.R.3633, the Digital Asset Market Clarity Act of 2025, but the calendar now marks it as “POSTPONED.” This markup, where lawmakers hash out amendments and decide on advancing the bill, has been delayed. (Senate Banking Committee)

Ripple highlighted a separate development, announcing it has gained preliminary approval for an electronic money institution licence in Luxembourg from the CSSF. This move is expected to boost Ripple Payments’ reach across the European Union. “The EU was amongst the first major jurisdictions to introduce comprehensive digital assets regulation,” said Ripple President Monica Long. (Ripple)

Banking Committee Chairman Tim Scott said bipartisan talks are ongoing, with “everyone remains at the table working in good faith” as lawmakers strive to establish “clear rules of the road.” (Senate Banking Committee)

Still, the delay highlighted a recurring risk in crypto: policy schedules often slip, and bill language can shift rapidly when banks and industry lobbyists apply pressure. That leaves tokens vulnerable if the market turns cautious.

Investors are turning their attention to the Senate Agriculture Committee next. Chairman John Boozman announced the panel aims to publish legislative text by the end of Jan. 21 and schedule a markup for 3 p.m. on Jan. 27. Traders will also be watching the Banking Committee for any reset date announcements, plus whether the updated wording keeps stablecoin rewards intact. (Senate Committee on Agriculture)

Stock Market Today

  • CAMP4 Therapeutics announces inducement grant under Nasdaq Rule 5635(c)(4)
    January 16, 2026, 5:39 PM EST. CAMP4 Therapeutics announced a non-qualified stock option award under Nasdaq Listing Rule 5635(c)(4) for a newly hired employee. The Inducement Grant covers 8,000 shares with a $5.78 exercise price, equal to the closing price on the grant date. The Grant Date was January 15, 2026, and the option has a ten-year term. Vesting occurs over four years: 25% after one year, with the remaining shares vesting in 36 equal monthly installments, subject to continued service. The award was granted by CAMP4's Compensation Committee under an Inducement Option Award Agreement. CAMP4 is a clinical-stage biopharma developing regulatory RNA-targeting therapeutics via its RAP Platform to upregulate gene expression for genetic diseases.
Bitcoin price wobbles near $95,000 after U.S. Senate delays CLARITY crypto bill
Previous Story

Bitcoin price wobbles near $95,000 after U.S. Senate delays CLARITY crypto bill

Go toTop